Antimetabolite + gastroprotective agent combination

This page covers all Antimetabolite + gastroprotective agent combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Dihydrofolate reductase (methotrexate); prostaglandin E1 receptor (misoprostol), COX-1/COX-2 (ibuprofen); H2 histamine receptor (famotidine).

Targets

Dihydrofolate reductase (methotrexate); prostaglandin E1 receptor (misoprostol) · COX-1/COX-2 (ibuprofen); H2 histamine receptor (famotidine)

Marketed (2)

• methotrexate + misoprostol · Wiebe, Ellen, M.D. · Oncology; Rheumatology
  Methotrexate inhibits dihydrofolate reductase to suppress cell proliferation, while misoprostol protects the gastrointestinal mucosa from methotrexate-induced damage.
• Zinc-l-carnosine · Fondazione IRCCS Policlinico San Matteo di Pavia · Gastroenterology
  Zinc-l-carnosine forms a chelate complex that protects and promotes healing of the gastrointestinal mucosa by reducing oxidative stress and enhancing mucosal defense mechanisms.

Phase 3 pipeline (2)

• CHOP Plus Famotidine · Sherief Abd-Elsalam · Oncology
  CHOP Plus Famotidine combines cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP chemotherapy) with famotidine, a histamine H2-receptor antagonist, to enhance chemotherapy efficacy and reduce gastric toxicity.
• Ibuprofen/famotidine · Amgen · Pain management / Gastroenterology
  This combination drug reduces stomach acid (via famotidine, an H2-receptor antagonist) while providing anti-inflammatory and analgesic effects (via ibuprofen, an NSAID), designed to minimize gastrointestinal injury from NSAID use.

Phase 2 pipeline (1)

• Ecabet 3.70% · Bausch & Lomb Incorporated · Gastrointestinal
  Ecabet is a gastroprotective agent that acts as a mucosal protective agent.

Patent intelligence

• gastroprotective agent patent landscape — aggregated cliff calendar, attackable patents, originator estates